The comparison of glycometabolism parameters and lipid profiles between drug-naïve, first-episode schizophrenia patients and healthy controls

Schizophrenia Research

Volumn 150, Issue 1, 2013, Pages 157-162

  Wu, Xiaoli ^a,b   Huang, Zeping ^b   Wu, Renrong ^a   Zhong, Zhiyong ^b   Wei, Qinling ^b   Wang, Houliang ^b   Diao, Feici ^b   Wang, Jihui ^b   Zheng, Liangrong ^b   Zhao, Jingping ^a   Zhang, Jinbei ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Drug na ve; First episode; Glycometabolism parameters; Healthy controls; Lipid profiles; Schizophrenia

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; C PEPTIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHINESE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ETHNICITY; FEMALE; GLUCOSE METABOLISM; HIP CIRCUMFERENCE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

DRUG-NAÏVE; FIRST-EPISODE; GLYCOMETABOLISM PARAMETERS; HEALTHY CONTROLS; LIPID PROFILES; SCHIZOPHRENIA;

ADOLESCENT; ADULT; APOLIPOPROTEINS A; BLOOD GLUCOSE; BODY MASS INDEX; C-PEPTIDE; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, HDL; FASTING; FEMALE; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; LIPIDS; MALE; OBSERVATION; PROSPECTIVE STUDIES; SCHIZOPHRENIA; WAIST-HIP RATIO; YOUNG ADULT;

EID: 84884158988     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.07.051     Document Type: Article

References (39)

1. Adams P.F., Marano M.A. Current estimates from the National Health Interview Survey, 1994. Vital Health Stat. 1995, 10(193 Pt 1):1-260.
2. Arai Y., Kojima T., Takayama M., Hirose N. The metabolic syndrome, IGF-1, and insulin action. Mol. Cell. Endocrinol. 2009, 299(1):124-128.
3. Arranz B., Rosel P., Ramirez N., Duenas R., Fernandez P., Sanchez J.M., Navarro M.A., San L. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J. Clin. Psychiatry 2004, 65(10):1335-1342.
4. Bernstein J.G. Induction of obesity by psychotropic drugs. Ann. N. Y. Acad. Sci. 1987, 499:203-215.
5. Boehm G., Racoosin J.A., Laughren T.P., Katz R. Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. Diabetes Care 2004, 27(8):2089-2090. (2088-2089).
6. Brown S., Birtwistle J., Roe L., Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol. Med. 1999, 29(3):697-701.
7. Casey D.E., Haupt D.W., Newcomer J.W., Henderson D.C., Sernyak M.J., Davidson M., Lindenmayer J.P., Manoukian S.V., Banerji M.A., Lebovitz H.E., Hennekens C.H. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J. Clin. Psychiatry 2004, 65(Suppl. 7):4-18. (19-20).
8. Citrome L.L. Antipsychotic medication and diabetes mellitus. J. Clin. Psychiatry 2005, 66(3):395.
9. Cohen D., Stolk R.P., Grobbee D.E., Gispen-de W.C. Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders. Diabetes Care 2006, 29(4):786-791.
10. Dasgupta A., Singh O.P., Rout J.K., Saha T., Mandal S. Insulin resistance and metabolic profile in antipsychotic naive schizophrenia patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34(7):1202-1207.
11. Dixon L., Weiden P., Delahanty J., Goldberg R., Postrado L., Lucksted A., Lehman A. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr. Bull. 2000, 26(4):903-912.
12. Fernandez-Egea E., Bernardo M., Parellada E., Justicia A., Garcia-Rizo C., Esmatjes E., Conget I., Kirkpatrick B. Glucose abnormalities in the siblings of people with schizophrenia. Schizophr. Res. 2008, 103(1-3):110-113.
13. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972, 18(6):499-502.
14. Guest P.C., Wang L., Harris L.W., Burling K., Levin Y., Ernst A., Wayland M.T., Umrania Y., Herberth M., Koethe D., van Beveren J.M., Rothermundt M., McAllister G., Leweke F.M., Steiner J., Bahn S. Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naive schizophrenia patients. Mol. Psychiatry 2010, 15(2):118-119.
15. Haffner S.M., Miettinen H., Stern M.P. The homeostasis model in the San Antonio Heart Study. Diabetes Care 1997, 20(7):1087-1092.
16. Holt R.I., Simpson H.L., Sonksen P.H. The role of the growth hormone-insulin-like growth factor axis in glucose homeostasis. Diabet. Med. 2003, 20(1):3-15.
17. Howes O.D., Gaughran F.P., Amiel S.A., Murray R.M., Pilowsky L.S. The effect of clozapine on factors controlling glucose homeostasis. J. Clin. Psychiatry 2004, 65(10):1352-1355.
18. Huang T.L., Chen J.F. Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan. Schizophr. Res. 2005, 80(1):55-59.
19. Kamran A., Doraiswamy P.M., Jane J.L., Hammett E.B., Dunn L. Severe hyperglycemia associated with high doses of clozapine. Am. J. Psychiatry 1994, 151(9):1395.
20. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
21. Leslie D.L., Rosenheck R.A. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am. J. Psychiatry 2004, 161(9):1709-1711.
22. Mansfield E., McPherson R., Koski K.G. Diet and waist-to-hip ratio: important predictors of lipoprotein levels in sedentary and active young men with no evidence of cardiovascular disease. J. Am. Diet. Assoc. 1999, 99(11):1373-1379.
23. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., Meltzer H.Y., Hsiao J., Scott S.T., Lieberman J.A. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 2005, 80(1):19-32.
24. Meyer J.M. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1year. J. Clin. Psychiatry 2002, 63(5):425-433.
25. Mukherjee S., Schnur D.B., Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet 1989, 1(8636):495.
26. Palik E., Birkas K.D., Faludi G., Karadi I., Cseh K. Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics. Diabetes Res. Clin. Pract. 2005, 68(Suppl.1):S60-S64.
27. Poyurovsky M., Pashinian A., Gil-Ad I., Maayan R., Schneidman M., Fuchs C., Weizman A. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. Am. J. Psychiatry 2002, 159(6):1058-1060.
28. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37(12):1595-1607.
29. Ryan M.C., Thakore J.H. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci. 2002, 71(3):239-257.
30. Ryan M.C., Collins P., Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am. J. Psychiatry 2003, 160(2):284-289.
31. Sengupta S., Parrilla-Escobar M.A., Klink R., Fathalli F., Ying K.N., Stip E., Baptista T., Malla A., Joober R. Are metabolic indices different between drug-naive first-episode psychosis patients and healthy controls?. Schizophr. Res. 2008, 102(1-3):329-336.
32. Spelman L.M., Walsh P.I., Sharifi N., Collins P., Thakore J.H. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet. Med. 2007, 24(5):481-485.
33. Taguchi A., Wartschow L.M., White M.F. Brain IRS2 signaling coordinates life span and nutrient homeostasis. Science 2007, 317(5836):369-372.
34. Thakore J.H., Mann J.N., Vlahos I., Martin A., Reznek R. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int. J. Obes. Relat. Metab. Disord. 2002, 26(1):137-141.
35. Venkatasubramanian G., Chittiprol S., Neelakantachar N., Naveen M.N., Thirthall J., Gangadhar B.N., Shetty K.T. Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am. J. Psychiatry 2007, 164(10):1557-1560.
36. Wen F., Tan J. Effects of phenothiazine drugs on serum levels of apolipoproteins and lipoproteins in schizophrenic subjects. Acta. Pharmacol. Sin. 2003, 24(10):1001-1005.
37. Wu R.R., Zhao J.P., Liu Z.N., Zhai J.G., Guo X.F., Guo W.B., Tang J.S. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl) 2006, 186(4):572-578.
38. Yang J., Liu X., Liu X., Wang L., Lv H., Yu J., Xun Z., Yang G. Abnormality of glycometabolism related factors in non-psychotic offspring of schizophrenic patients. Psychiatry Res. 2012, 198(2):183-186.
39. Yogaratnam J., Biswas N., Vadivel R., Jacob R. Metabolic complications of schizophrenia and antipsychotic medications-an updated review. East. Asian. Arch. Psychiatry 2013, 23(1):21-28.